Clinical results of IMAT in adenocarcinoma prostate cancer

被引：0
|
作者：
Gribaudo, S. [1 ]
Monetti, U. [1 ]
Mussano, A. [1 ]
La Sala, S. [1 ]
Di Gregorio, S. [1 ]
Richetto, V. [1 ]
Sardo, A. [1 ]
Trevisiol, E. [1 ]
Madon, E. [1 ]
Urgesi, A. [1 ]
机构：
[1] OIRM, S Anna Hosp, Turin, Italy
来源：
RADIOTHERAPY AND ONCOLOGY | 2006年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1079
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [41] UROTENSIN II RECEPTOR IS INVOLVED IN THE REGULATION OF MOTILITY OF PROSTATE ADENOCARCINOMA CELLS AND PREDICTS THE CLINICAL OUTCOME OF PROSTATE CANCER PATIENTS
    Caraglia, M.
    Marra, M.
    Franco, R.
    Sgambato, A.
    Zappavigna, S.
    Striano, S.
    Marra, L.
    Gallo, L.
    Botti, G.
    Ferro, M.
    Altieri, V.
    Novellino, E.
    Molinari, A.
    Budillon, A.
    Grieco, P.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1531 - 1532
  • [42] Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres
    Lopes de Castro, Carla
    Fundowicz, Magdalena
    Rosello, Alvar
    Jove, Josep
    Deantonio, Letizia
    Aguiar, Artur
    Pisani, Carla
    Villa, Salvador
    Boladeras, Anna
    Konstanty, Ewelina
    Kruszyna-Mochalska, Marta
    Milecki, Piotr
    Jurado-Bruggeman, Diego
    Lencart, Joana
    Modolell, Ignasi
    Munoz-Montplet, Carles
    Aliste, Luisa
    Torras, Maria Gloria
    Puigdemont, Montserrat
    Carvalho, Luisa
    Krengli, Marco
    Guedea, Ferran
    Malicki, Julian
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres
    Carla Lopes de Castro
    Magdalena Fundowicz
    Alvar Roselló
    Josep Jové
    Letizia Deantonio
    Artur Aguiar
    Carla Pisani
    Salvador Villà
    Anna Boladeras
    Ewelina Konstanty
    Marta Kruszyna-Mochalska
    Piotr Milecki
    Diego Jurado-Bruggeman
    Joana Lencart
    Ignasi Modolell
    Carles Muñoz-Montplet
    Luisa Aliste
    Maria Gloria Torras
    Montserrat Puigdemont
    Luísa Carvalho
    Marco Krengli
    Ferran Guedea
    Julian Malicki
    Scientific Reports, 11
  • [44] Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model
    Raghow, S
    Hooshdaran, MZ
    Katiyar, S
    Steiner, MS
    CANCER RESEARCH, 2002, 62 (05) : 1370 - 1376
  • [45] Plasmacytoid acinar adenocarcinoma of the prostate: a newly described variant of prostate cancer
    Al-Hussain, Turki
    Haffner, Michael C.
    Altaweel, Waleed M.
    Epstein, Jonathan I.
    HUMAN PATHOLOGY, 2019, 94 : 86 - 91
  • [46] Macrocystic ductal adenocarcinoma of prostate: A rare gross appearance of prostate cancer
    Kojima, Fumiyoshi
    Koike, Hiroyuki
    Matsuzaki, Ibu
    Iwahashi, Yoshifumi
    Warigaya, Kenji
    Fujimoto, Masakazu
    Ono, Kazuo
    Urata, Youji
    Kohjimoto, Yasuo
    Hara, Isao
    Murata, Shin-ichi
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 27 : 7 - 13
  • [47] IMMUNOLYMPHOSCINTIGRAPHY IN PROSTATE-CANCER - 1ST CLINICAL-RESULTS
    TEILLAC, P
    LEROY, M
    RAIN, JD
    BRUNEAU, J
    CHEVAL, E
    KETELS, F
    RABAUD, B
    SACCAVINI, JC
    NAJEAN, Y
    LEDUC, A
    ANNALES DE MEDECINE INTERNE, 1989, 140 (01): : 20 - 24
  • [48] Folic Acid and Risk of Prostate Cancer: Results From a Randomized Clinical Trial
    Figueiredo, Jane C.
    Grau, Maria V.
    Haile, Robert W.
    Sandler, Robert S.
    Summers, Robert W.
    Bresalier, Robert S.
    Burke, Carol A.
    McKeown-Eyssen, Gail E.
    Baron, John A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (06): : 432 - 435
  • [49] Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies
    Armstrong A.J.
    Carducci M.A.
    Current Oncology Reports, 2005, 7 (3) : 220 - 227
  • [50] Clinical Results from the Simultaneous Hypofractionated Radiotherapy for Prostate Cancer (SHaRP) Study
    Staffurth, J.
    CLINICAL ONCOLOGY, 2011, 23 (03) : S54 - S54
12345